160 related articles for article (PubMed ID: 22498112)
1. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Eberhardt WE; de Marinis F; Heeger S; Goddemeier T; O'Byrne KJ; Gatzemeier U
Lung Cancer; 2012 Aug; 77(2):376-82. PubMed ID: 22498112
[TBL] [Abstract][Full Text] [Related]
2. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
3. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
[TBL] [Abstract][Full Text] [Related]
4. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in stage III non-small-cell lung cancer.
Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials.
Di Maio M; Signoriello S; Morabito A; Rossi A; Maione P; Piantedosi F; Bilancia D; Cigolari S; Barbera S; Gebbia V; Daniele B; Robbiati SF; Illiano A; Ceribelli A; Carrozza F; Favaretto A; Piazza E; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2012 Jun; 76(3):457-64. PubMed ID: 22297086
[TBL] [Abstract][Full Text] [Related]
7. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
8. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.
Di Maio M; Lama N; Morabito A; Smit EF; Georgoulias V; Takeda K; Quoix E; Hatzidaki D; Wachters FM; Gebbia V; Tsai CM; Camps C; Schuette W; Chiodini P; Piccirillo MC; Perrone F; Gallo C; Gridelli C
Eur J Cancer; 2010 Mar; 46(4):735-43. PubMed ID: 20045311
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
[TBL] [Abstract][Full Text] [Related]
10. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
12. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
Spigel DR; Anthony Greco F; Waterhouse DM; Shipley DL; Zubkus JD; Bury MJ; Webb CD; Hart LL; Gian VG; Infante JR; Burris HA; Hainsworth JD
Lung Cancer; 2012 Oct; 78(1):70-5. PubMed ID: 22947511
[TBL] [Abstract][Full Text] [Related]
15. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
Tsao AS; Liu D; Lee JJ; Spitz M; Hong WK
Cancer; 2006 Jun; 106(11):2428-36. PubMed ID: 16634096
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
17. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
18. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
19. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Schnabel PA; Smit E; Carpeño Jde C; Leśniewski-Kmak K; Aerts J; Kraaij K; Visseren-Grul C; Dyachkova Y; Taipale K; Girvan A; Moro-Sibilot D
Lung Cancer; 2012 Dec; 78(3):263-9. PubMed ID: 23040326
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
